HPV E6 protein T cell epitopes and uses thereof
View Patent ↗The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.
1. A method of decreasing infection from human papilloma virus in an individual, comprising:
administering to the individual an immunologically effective amount of an immunogenic composition comprising a synthetic peptide comprising SEQ ID NO: 32, a synthetic peptide comprising SEQ ID NO: 33, a synthetic peptide comprising SEQ ID NO: 34, and a synthetic peptide comprising SEQ ID NO: 35; wherein said composition activates a specific immune response in the individual, thereby decreasing infection from human papilloma virus in the individual and wherein each synthetic peptide does not comprise full-length HPV E6 protein.
2. The method of claim 1 , wherein said synthetic peptides are acetylated at the amino terminus, amidated at the carboxyl terminus or acetylated at the amino terminus and amidated at the carboxyl terminus.
3. A method for increasing regression of Human Papilloma Virus (HPV)-associated cervical lesions in an HPV positive individual, comprising
administering an immunogenic composition comprising peptides derived from immunodominant epitopes of HPV E6 protein effective to generate CD8 T-cell responses specific against the HPV,
wherein the composition comprises peptides consisting of SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35.
4. The method of claim 3 , wherein said peptides are synthetic peptides acetylated at the amino terminus, amidated at the carboxyl terminus or acetylated at the amino terminus and amidated at the carboxyl terminus.
5. The method of claim 3 , wherein the immunogenic composition further comprises an adjuvant.
6. The method of claim 5 , wherein said adjuvant comprises antigens from Candida albicans , mumps virus, or Trichophyton.
7. The method of claim 6 , wherein said adjuvant is concentrated whole cell extract made from lyophilized cells of Candida albicans.
8. The method of claim 7 , wherein said adjuvant is contained in said composition in an antigen/adjuvant ratio of about 20 micrograms antigen per 200 microliter of adjuvant to about 20 micrograms antigen per 500 microliter of adjuvant.
9. The method of claim 8 , wherein said immunogenic composition is administered intradermally.
10. The method of claim 1 wherein the immunogenic composition further comprises an adjuvant, wherein immunization of mice with the immunogenic composition comprising the adjuvant enhances stimulation of interferon-gamma-expressing HPV-antigen-specific T cells as compared to immunization of mice with the immunogenic composition lacking the adjuvant.
11. The method of claim 4 wherein the peptides consisting of SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35 are each acetylated at the amino terminus and amidated at the carboxyl terminus.
12. The method of claim 11 wherein the composition further comprises an adjuvant, wherein said adjuvant comprises antigens from Candida albicans , mumps virus, or Trichophyton.
13. The method of claim 12 wherein the adjuvant comprises whole cell Candida albicans extract.
14. The method of claim 3 wherein the immunogenic composition further comprises an adjuvant, wherein immunization of mice with the immunogenic composition comprising the adjuvant enhances stimulation of interferon-gamma-expressing HPV-antigen-specific T cells as compared to immunization of mice with the immunogenic composition lacking the adjuvant.
15. A method of decreasing infection from human papilloma virus in an individual or increasing regression of Human Papilloma Virus (HPV)-associated cervical lesions in an HPV positive individual, comprising:
administering an immunogenic composition comprising:
(a) a peptide comprising SEQ ID NO: 32, a peptide comprising SEQ ID NO: 33, a peptide comprising SEQ ID NO: 34, and a peptide comprising SEQ ID NO: 35, wherein each peptide does not comprise full-length HPV E6 protein; and
(b) an adjuvant comprising antigens from Candida albicans , mumps virus, or Trichophyton.
16. The method of claim 15 wherein the adjuvant is concentrated whole cell extract made from lyophilized cells of Candida albicans.
17. The method of claim 15 wherein the method comprises administering the immunogenic composition intradermally.
18. The method of claim 1 wherein the immunogenic composition comprises synthetic peptides consisting of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
19. The method of claim 15 wherein the at least one peptide is a synthetic peptide acetylated at the amino terminus, amidated at the carboxyl terminus or acetylated at the amino terminus and amidated at the carboxyl terminus.
20. The method of claim 15 wherein the peptides consist of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.